Targeting SHP2 as a promising strategy for cancer immunotherapy
Authors:
- 1 February 2020
- journal article
- review article
- Published by Elsevier in Pharmacological Research
- Vol. 152, 104595
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (81872877, 91853109, 81673436, 81730100)
- Fundamental Research Funds for the Central Universities (0208-14380128)
- Mountain-Climbing Talents Project of Nanjing University
This publication has 99 references indexed in Scilit:
- Loss of SHP-2 activity in CD4+ T cells promotes melanoma progression and metastasisScientific Reports, 2013
- Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2Journal of Experimental Medicine, 2012
- Conflicting Roles of Molecules in Hepatocarcinogenesis: Paradigm or ParadoxCancer Cell, 2012
- Ptpn11/Shp2 Acts as a Tumor Suppressor in Hepatocellular CarcinogenesisCancer Cell, 2011
- Shp2 protein tyrosine phosphatase inhibitor activity of estramustine phosphate and its triterpenoid analogsBioorganic & Medicinal Chemistry Letters, 2011
- Interferon-γ Is Induced in Human Peripheral Blood Immune Cells In Vitro by Sodium Stibogluconate/Interleukin-2 and Mediates Its Antitumor Activity In VivoJournal of Interferon & Cytokine Research, 2009
- Phase II Trial of Consolidation Docetaxel and Samarium-153 in Patients With Bone Metastases From Castration-Resistant Prostate CancerJournal of Clinical Oncology, 2009
- SHP‐1 and SHP‐2 in T cells: two phosphatases functioning at many levelsImmunological Reviews, 2009
- Specific inhibitors of the protein tyrosine phosphatase Shp2 identified by high-throughput dockingProceedings of the National Academy of Sciences, 2008
- Protein-tyrosine phosphatases and cancerNature Reviews Cancer, 2006